🇺🇸 FDA
Patent

US 11015200

Antisense-induced exon exclusion in myostatin

granted A61KA61K31/7105A61P

Quick answer

US patent 11015200 (Antisense-induced exon exclusion in myostatin) held by Sarepta Therapeutics, Inc. expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sarepta Therapeutics, Inc.
Grant date
Tue May 25 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/7105, A61P, A61P21/00